UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.326

Sortiert nach

Microtubule-targeted anticancer agents and apoptosis

Oncogene, 2003-12, Vol.22 (56), p.9075-9086

Bhalla, Kapil N

2003

Volltextzugriff (PDF)

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

Leukemia, 2014-11, Vol.28 (11), p.2155-2164

2014

Volltextzugriff (PDF)

Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies

Journal of clinical oncology, 2005-06, Vol.23 (17), p.3971-3993

BHALLA, Kapil N

2005

Volltextzugriff (PDF)

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells

Leukemia, 2017-09, Vol.31 (9), p.1951-1961

2017

Volltextzugriff (PDF)

Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia

Cancer research (Chicago, Ill.), 2014-05, Vol.74 (9), p.2520-2532

2014

Volltextzugriff (PDF)

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

Leukemia, 2017-03, Vol.31 (3), p.678-687

2017

Volltextzugriff (PDF)

Spatial transcriptomics landscape of lesions from non-communicable inflammatory skin diseases

Nature communications, 2022-12, Vol.13 (1), p.7729-7729, Article 7729

2022

Volltextzugriff (PDF)

BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells

Leukemia, 2018-02, Vol.32 (2), p.343-352

2018

Volltextzugriff (PDF)

Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy

Proceedings of the National Academy of Sciences - PNAS, 2013-04, Vol.110 (17), p.6841-6846

2013

Volltextzugriff (PDF)

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Nature communications, 2021-05, Vol.12 (1), p.2607-2607, Article 2607

2021

Volltextzugriff (PDF)

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1

Blood, 2019-07, Vol.134 (1), p.59-73

2019

Volltextzugriff (PDF)

Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells

Molecular cancer therapeutics, 2014-05, Vol.13 (5), p.1142-1154

2014

Volltextzugriff (PDF)

rec-1 loss of function increases recombination in the central gene clusters at the expense of autosomal pairing centers

Genetics (Austin), 2024-03, Vol.226 (3)

2024

Volltextzugriff (PDF)

Molecular mechanisms for environmentally induced and evolutionarily rapid redistribution (plasticity) of meiotic recombination

Genetics (Austin), 2022-02, Vol.220 (2)

2022

Volltextzugriff (PDF)

Automated reporter quantification in vivo: high-throughput screening method for reporter-based assays in zebrafish

PloS one, 2012-01, Vol.7 (1), p.e29916-e29916

2012

Volltextzugriff (PDF)

Aptamer-based Field-Effect Biosensor for Tenofovir Detection

Scientific reports, 2017-03, Vol.7 (1), p.44409-44409, Article 44409

2017

Volltextzugriff (PDF)

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib

Blood, 2015-09, Vol.126 (13), p.1565-1574

2015

Volltextzugriff (PDF)

Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells

Molecular cancer therapeutics, 2013-05, Vol.12 (5), p.577-588

2013

Volltextzugriff (PDF)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Blood cancer journal (New York), 2022-01, Vol.12 (1), p.5-5, Article 5

2022

Volltextzugriff (PDF)

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

Leukemia, 2015-06, Vol.29 (6), p.1267-1278

2015

Volltextzugriff (PDF)

Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells

Molecular cancer therapeutics, 2012-04, Vol.11 (4), p.973-983

2012

Volltextzugriff (PDF)

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies

Blood cancer journal (New York), 2021-03, Vol.11 (3), p.64-64, Article 64

2021

Volltextzugriff (PDF)

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

Nature medicine, 2009-12, Vol.15 (12), p.1369-1376

2009

Volltextzugriff (PDF)

Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia

Cancer research (Chicago, Ill.), 2005-01, Vol.65 (2), p.613-621

2005

Volltextzugriff (PDF)

1 – 25 von 1.326

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.144)
Mit Volltextzugriff
(1.144)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(103)
Cancer Research
(46)
Journal Of Clinical Oncology
(31)
Leukemia
(25)
Indian Pediatrics
(24)
Physical Review Letters
(23)
Nuclear Physics. A
(16)
Journal Of The Association Of Physicians Of India
(15)
Ferroelectrics
(14)
Indian Journal Of Pediatrics
(13)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Microtubule-targeted anticancer agents and apoptosis

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells

Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells

Spatial transcriptomics landscape of lesions from non-communicable inflammatory skin diseases

BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells

Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1

Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells

rec-1 loss of function increases recombination in the central gene clusters at the expense of autosomal pairing centers

Molecular mechanisms for environmentally induced and evolutionarily rapid redistribution (plasticity) of meiotic recombination

Automated reporter quantification in vivo: high-throughput screening method for reporter-based assays in zebrafish

Aptamer-based Field-Effect Biosensor for Tenofovir Detection

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib

Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells

Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia

Suchergebnisse filtern